RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$45.77
−3.95%Margins
Gross margin
100.0%
EBITDA margin
-740.7%
EBIT margin
-767.6%
Net margin
-685.8%
FCF margin
-485.7%
-32.4%
Return on equity
-29.9%
Return on assets
-35.5%
Return on invested capital
0.04x
Asset turnover
-$96.7M
Cash from operations
$9.09
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026